CMPS vs LLY vs PFE vs ABBV

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate COMPASS Pathways plc (CMPS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 5x versus AbbVie Inc. at 86. 5x. On forward P/E, Pfizer Inc. is actually cheaper at 9. 0x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.

4%, compared to -71. 8% for COMPASS Pathways plc (CMPS). Over 10 years, the gap is even starker: LLY returned +1272% versus CMPS's -66. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus COMPASS Pathways plc's 1. 33β — meaning CMPS is approximately 293% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -33. 9% for COMPASS Pathways plc. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus 0. 0% for COMPASS Pathways plc — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for CMPS. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 9. 0x forward P/E versus 28. 6x for Eli Lilly and Company — 19. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CMPS: 82. 7% to $17. 83.

In this comparison, PFE (6.

5% yield), ABBV (3. 2% yield), LLY (0. 6% yield) pay a dividend. CMPS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1272% 10Y return). Both have compounded well over 10 years (LLY: +1272%, CMPS: -66. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CMPS is a small-cap quality compounder stock; LLY is a large-cap high-growth stock; PFE is a mid-cap income-oriented stock; ABBV is a large-cap income-oriented stock. LLY, PFE, ABBV pay a dividend while CMPS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.